|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCNMB3 |
Gene summary for KCNMB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCNMB3 | Gene ID | 27094 |
| Gene name | potassium calcium-activated channel subfamily M regulatory beta subunit 3 | |
| Gene Alias | BKBETA3 | |
| Cytomap | 3q26.32 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q9NPA1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27094 | KCNMB3 | HCC1_Meng | Human | Liver | HCC | 1.63e-39 | 1.66e-01 | 0.0246 |
| 27094 | KCNMB3 | HCC2_Meng | Human | Liver | HCC | 6.21e-06 | 6.23e-02 | 0.0107 |
| 27094 | KCNMB3 | HCC1 | Human | Liver | HCC | 5.67e-13 | 3.11e+00 | 0.5336 |
| 27094 | KCNMB3 | HCC2 | Human | Liver | HCC | 2.53e-18 | 2.22e+00 | 0.5341 |
| 27094 | KCNMB3 | HCC5 | Human | Liver | HCC | 6.74e-06 | 1.81e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Oral cavity | OSCC |  |
| Oral cavity | LP |  |
| Oral cavity | EOLP |  |
| Oral cavity | NEOLP |  |
| Esophagus | HGIN |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
| GO:005159221 | Liver | HCC | response to calcium ion | 81/7958 | 149/18723 | 2.26e-03 | 1.13e-02 | 81 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCNMB3 | SNV | Missense_Mutation | novel | c.625N>A | p.Ala209Thr | p.A209T | Q9NPA1 | protein_coding | tolerated(0.07) | benign(0.265) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | c.222C>A | p.Phe74Leu | p.F74L | Q9NPA1 | protein_coding | deleterious(0) | possibly_damaging(0.709) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| KCNMB3 | SNV | Missense_Mutation | novel | c.296N>G | p.His99Arg | p.H99R | Q9NPA1 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | rs764992727 | c.52C>T | p.Arg18Cys | p.R18C | Q9NPA1 | protein_coding | deleterious(0.05) | benign(0.003) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | novel | c.416N>T | p.Ala139Val | p.A139V | Q9NPA1 | protein_coding | tolerated(0.5) | benign(0.217) | TCGA-A5-AB3J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| KCNMB3 | SNV | Missense_Mutation | novel | c.638N>A | p.Cys213Tyr | p.C213Y | Q9NPA1 | protein_coding | deleterious(0) | possibly_damaging(0.598) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | novel | c.241N>A | p.Leu81Ile | p.L81I | Q9NPA1 | protein_coding | tolerated(0.07) | probably_damaging(0.918) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | novel | c.96N>T | p.Lys32Asn | p.K32N | Q9NPA1 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | novel | c.106N>T | p.Asp36Tyr | p.D36Y | Q9NPA1 | protein_coding | tolerated(0.23) | benign(0.005) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNMB3 | SNV | Missense_Mutation | c.389N>C | p.Val130Ala | p.V130A | Q9NPA1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BS-A0UA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |